AIM To investigate the therapeutic effect of adjusted betaloc dose based on target heart rate in the treatment of coronary heart disease.
METHODS A total of 100 patients with coronary heart disease admitted to our hospital from June 2018 to December 2019 were randomly divided into target dose group and target heart rate group, with 50 patients in each group. In addition to other fixed secondary prevention drugs for coronary heart disease, the dose of betaloc was added step by step to target dose (50 mg, bid) in target dose group, while the dose was adjusted to the maximum tolerance dose step by step guided by target heart rate (55-60 bpm) in target heart rate group. The cardiac function of the two groups was compared after drug administration. The evaluation criteria included New York cardiac function rating, 6-minute walking test and echocardiographic indicators.
RESULTS Compared with those before treatment, the results of echocardiography (LVEDD, LVEF) and 6-minute walking test were significantly improved in both groups after treatment (P<0.05). The LVEDD in target heart rate group was significantly lower than that in target dose group (P<0.01), while the LVEF value target heart rate group was significantly higher than that in target dose group (P<0.01). The 6-minute walking test results of patients in target heart rate group were significantly higher than those in target dose group (P<0.05). After treatment, statistically significant difference was observed by New York heart function classification between target dose group ( class Ⅱ: 29 cases, 58% ; class Ⅲ: 21cases, 42%) and target heart rate group (class Ⅱ: 39 cases, 78% ; class Ⅲ:11 cases, 22%)
CONCLUSION The target heart rate group is more effective in the treatment of coronary heart disease.
DownLoad: